. 2018; 27(2): 0-0 | |||
I-131 Radiation-Induced Myelosuppression in Differentiated Thyroid Cancer TherapyStephan Probst1, Gad Abikhzer1, Guillaume Chaussé1, Michael Tamilia21Jewish General Hospital, Nuclear Medicine2Jewish General Hospital, Endocrinology Radioactive iodine (RAI) treatment of differentiated thyroid cancer (DTC) has been used in clinical practice for almost 60 years and is generally accepted to be a safe and efficacious treatment. Severe toxicity in the form of radiation pneumonitis, sometimes progressing to fibrosis, and bone marrow suppression are reported but remain rare. We present a case of severe myelosuppression requiring hospitalization and transfusion support in an otherwise well, young female patient who had received 175 mCi I-131 for low-volume micronodular lung disease one month prior, with a cumulative lifetime administered activity of 575 mCi. The most important risk factors for myelosuppression following RAI are the activity received, the amount of functioning thyroid tissue present, and the lifetime cumulative activity received. Keywords: Radioactive Iodine, Myelosuppression, Differentiated Thyroid cancer, Metastatic Thyroid cancer, Iodine-131 therapyStephan Probst, Gad Abikhzer, Guillaume Chaussé, Michael Tamilia. I-131 Radiation-Induced Myelosuppression in Differentiated Thyroid Cancer Therapy. . 2018; 27(2): 0-0 Corresponding Author: Guillaume Chaussé, Canada |
|